Seeking Alpha

Roy Manning III

View Roy Manning III's StockTalks BY TICKER:
  • Roy Manning III
    Quest Diagnostics Has An Improved Outlook After Summit Health Acquisition And $600 Million Refinancing $DGX http://seekingalpha.com/a/18pr7
    Mar 13, 9:39 AM
    Reply
      • Roy Manning III
        CareFusion Corporation's Recent Takeovers And Partnerships Promise A 20% Rise In Price $CFN http://seekingalpha.com/a/18kf9
        Mar 10, 6:54 PM
        Reply
          • Roy Manning III
            Starwood Hotels & Resorts Worldwide, Inc. Rallies To New Highs $MAR, $HOT http://seekingalpha.com/p/1lzl5
            Feb 25, 5:32 PM
            Reply
              • Roy Manning III
                Lennar Corporation: The Spring Rally Is Here $LEN http://seekingalpha.com/a/17rhl
                Feb 23, 3:37 PM
                Reply
                  • Roy Manning III
                    LEN: The spring rally is starting. Resistance at $42 must be penetrated. New Highs by summer.
                    Feb 23, 8:00 AM
                    Reply
                      • Roy Manning III
                        SGYP may be a good buy right now. It raised 42m. Its constipation drug looks great. IRWD has a similar drug and It's valued at 1.3 billion.
                        5/11/12
                        Reply
                          • Roy Manning III
                            ARRY is a good buy. Expecting $20 million in milestone payments by end of year. Payments from partners keep this stock profitable.
                            5/8/12
                            Reply
                              • Roy Manning III
                                BCRX has sold off alot. I would consider it a buy now. News on a Gout drug partner or their Hep C. patent could push the stock higher.
                                5/7/12
                                Reply
                                  • Roy Manning III
                                    SCLN is up over 5% today. Check out my article.
                                    4/9/12
                                    Reply
                                      • Roy Manning III
                                        Working on an article on RNN. New focus on cancer drugs looks good to me. Possible partnership on Archexin when results come in Q3.
                                        3/29/12
                                        Reply (1)
                                        • PAULNMYSTI: Thinking the same. This drug has blockbuster potential, since it will be the first of its kind in treating pancreatic cancer.
                                          7/19/12
                                          • Roy Manning III
                                            Pozen has been adding a little each day. Maybe I was not wrong about the possible return on pos. study results.
                                            3/29/12
                                            Reply
                                              • Roy Manning III
                                                POZN price did not move much- it was only up 14% early in the day and ended the day up 8.75%. On a major study I expect 20-40%.
                                                3/22/12
                                                Reply
                                                  • Roy Manning III
                                                    POZN is up over 14% on positive results on their Ulcer Safe Aspirin. Look for further gains as they find a partner or buyout.
                                                    3/22/12
                                                    Reply
                                                      • Roy Manning III
                                                        NYMX continues to hold on as we wait for stage III trial to fill up. Offers a cure for Enlarged Prostate that works twice as well as pills.
                                                        3/19/12
                                                        Reply
                                                          • Roy Manning III
                                                            ZLCS-Zalicus value @100m 2b Synavive over 2h '12. Z160 for neuro pain starts stage 2in 2h '12. Z944 for acute pain soon stage2 watch Z160.
                                                            3/18/12
                                                            Reply
                                                              • Roy Manning III
                                                                POZN has $7 a share potential with Ulcer free aspirin study ending in march. Low cash burn since studies are over - $110m in cash.
                                                                3/17/12
                                                                Reply
                                                                  • Roy Manning III
                                                                    ATRS has be inching upwards. Look for this to continue as good results in Libigel trials continue to come in. AIS also has many other drugs.
                                                                    7/10/11
                                                                    Reply
                                                                      • Roy Manning III
                                                                        VICL has a new cancer vacine A-7. The final study results should be in by feb 2012 at the latest. If results are pos. the stock could go up.
                                                                        7/10/11
                                                                        Reply
                                                                          • Roy Manning III
                                                                            AEZS has a new colon cancer drug P. The final trial should show results this fall. If the results are good the stock should go higher.
                                                                            7/10/11
                                                                            Reply
                                                                              • Roy Manning III
                                                                                APRI has potential for its sexual drugs (male and female). Its been accepted in Canada and is applying for Euro which send it much higher.
                                                                                7/10/11
                                                                                Reply